Benoxi (Drops) Instructions for Use
Marketing Authorization Holder
Unimed Pharma, s.r.o. (Slovakia)
ATC Code
S01HA02 (Oxybuprocaine)
Active Substance
Oxybuprocaine (Rec.INN registered by WHO)
Dosage Form
| Benoxi | Eye drops 4 mg/1 ml: 10 ml dropper bottle |
Dosage Form, Packaging, and Composition
Eye drops as a clear, colorless solution.
| 1 ml | 1 bottle | |
| Oxybuprocaine hydrochloride | 4 mg | 40 mg |
Excipients: boric acid – 200 mg, chlorhexidine diacetate – 1 mg, purified water – up to 10 ml.
10 ml – plastic dropper bottles (1) – cardboard packs.
Clinical-Pharmacological Group
Local anesthetic for use in ophthalmology
Pharmacotherapeutic Group
Local anesthetic agent
Pharmacological Action
Local anesthetic for use in ophthalmology.
It causes a reversible block of the propagation and conduction of nerve impulses through the axons of nerve cells.
Pharmacokinetics
It is easily absorbed through the mucous membranes into the corneal stroma after a single instillation into the conjunctival sac.
Anesthesia occurs within 1-3 minutes.
During the subsequent 15 minutes, a quantitative decrease in the stromal concentration of oxybuprocaine is observed, which provides a 15-20 minute period of anesthesia after a single instillation.
Indications
Local anesthesia in ophthalmology (including superficial anesthesia of the cornea and conjunctiva) for tonometry, gonioscopy and other diagnostic examinations, before performing subconjunctival injections, for removal of foreign bodies and sutures from the cornea and conjunctiva, for short-term surgical interventions on the cornea and conjunctiva.
ICD codes
| ICD-10 code | Indication |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer topically as instillations into the conjunctival sac.
For tonometry and other brief diagnostic procedures, instill 1-2 drops immediately prior to the examination.
For removal of corneal foreign bodies or sutures, instill 1-2 drops several minutes before the procedure. A second instillation may be required.
For short surgical interventions, instill 1 drop every 2-3 minutes for a total of 1-3 instillations.
Adjust the regimen based on the clinical situation and required duration of anesthesia.
Do not exceed the minimum number of drops necessary to achieve adequate anesthesia.
Avoid prolonged or repeated use beyond the immediate procedural requirement to prevent corneal complications.
Adverse Reactions
From the organ of vision: sensation of burning and conjunctival hyperemia, transient tingling sensation; damage to the corneal epithelial layer, keratitis and excoriation of the corneal surface.
Allergic reactions: anaphylactic shock.
From the CNS: grand mal epileptic seizure, fainting.
From the cardiovascular system: bradycardia.
Contraindications
Hypersensitivity to oxybuprocaine; children under 2 years of age.
With caution in patients with pseudocholinesterase deficiency, malignant myasthenia, and patients with epilepsy.
Use in Pregnancy and Lactation
The use of oxybuprocaine during pregnancy and breastfeeding is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus or infant.
Pediatric Use
Contraindicated for use in children and adolescents under 2 years of age.
Special Precautions
The product is to be used only for instillation into the conjunctival sac.
Do not use for injections.
Prolonged, repeated and long-term use of oxybuprocaine (as well as other local anesthetics) may lead to persistent corneal clouding.
Oxybuprocaine is not intended for long-term therapy in complex eye disease.
During anesthesia, it is necessary to protect the eye from irritating chemical influences, foreign bodies and friction.
During treatment, alcohol consumption should be avoided.
Effect on the ability to drive vehicles and mechanisms
During treatment, patients should refrain from driving any vehicles and engaging in other activities that require high concentration and speed of psychomotor reactions.
Drug Interactions
Oxybuprocaine enhances the effect of succinylcholine and sympathomimetics, and reduces the effect of sulfonamides and beta-blockers.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer